Saronic Biotechnology, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapeutics for the treatment of hepatocellular carcinoma, the most prevalent type of liver cancer and the third-leading cause of cancer-related mortality worldwide. Composed of a team of clinicians, researchers, and laboratory scientists with extensive expertise in liver cancer, hepatitis, and immunology, Saronic Biotechnology is prepared to launch clinical evaluation of its lead therapeutic technology, SBI1997, in 2016.

For Investor Inquiries

Spiros Hiotis, M.D. Ph.D.
[email protected]
(212) 500-0595 Ext. 700